Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Don't Miss our Black Friday Offers: Roger Song’s rating is based on the promising potential of Aclaris Therapeutics’ BSI-045B, an anti-TSLP antibody that has demonstrated clinical proof of concept in ...

BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion’s regional partner, Chia Tai Tianqing ...

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

Biosion, Inc., a R&D stage biotechnology company, announced Monday that it has entered into an exclusive license agreement with ...

Biosion inks exclusive, global license pact with Aclaris Therapeutics on two potential first-in-class and best-in-class immunology assets: Newark, Delaware Wednesday, November 20, ...

Jefferies upgraded Aclaris Therapeutics (ACRS) to Buy from Hold with a price target of $7, up from $2. BSI-045B is the first anti-TSLP showing clinical proof of concept in atopic dermatitis, which is ...

Aclaris stock surges on inking an exclusive license agreement with Biosion for global rights to two of the latter's pipeline candidates, BSI-045B and BSI-502.

Aclaris Therapeutics has entered an exclusive licensing deal with Biosion for two antibodies, BSI-045B for atopic dermatitis ...

A %Healthcare company based out of Pennsylvania caused quite the stir on Tuesday after the company announced that it had ...

Under the agreement, Biosion will receive over $40 million cash as an upfront license fee and reimbursement for certain development costs and drug product materials. Biosion said it will receive 19.9% ...